Amneal Pharmaceuticals, Inc. (AMRX) — Fair Value Analysis

Base-case fair value (P50): $13.04 · Current price: $12.31 · Verdict: Fairly Valued

The Verdict on AMRX

Based on our latest Monte Carlo simulations, AMNEAL PHARMACEUTICALS INC CLASS A (AMRX) is currently deemed Fairly Valued. The analysis indicates a median fair value (P50) of $13.04 against its current price of $12.31. This represents a potential upside of +5.9% from the current trading level, suggesting the market is largely aligned with its intrinsic value derived from thousands of forward-looking scenarios. While there is a modest positive gap, the simulations do not indicate significant overvaluation or undervaluation for AMRX at its current price, affirming its Fairly Valued status.

How AMRX stacks up against Healthcare

AMRX’s operational and financial health is categorized as average compared to its peers within the Healthcare sector. This average quality tier directly influences its valuation profile, anchoring the median fair value (P50) of $13.04 in line with its fundamental performance and sector positioning. While the current price of $12.31 shows a slight discrepancy to the P50, the modest +5.9% potential upside is consistent with a company whose core health is deemed average relative to the broader industry, limiting extreme deviations in its simulated fair value. A company with average quality is less likely to show a large fair value gap.

What this means for investors

For investors considering AMNEAL PHARMACEUTICALS INC CLASS A, the Monte Carlo analysis suggests AMRX is Fairly Valued. The current price of $12.31 sits close to the median fair value (P50) of $13.04, reflecting a modest +5.9% gap. This narrow spread, coupled with an average quality tier, implies the stock is trading efficiently based on its current fundamentals and projected future scenarios. While a slight upside exists in the base case, it doesn't indicate a compelling undervaluation or significant overvaluation based on these simulations, which factor in thousands of potential outcomes. For a deeper understanding of AMRX's full bear and bull case distribution and to track its fair value as new fundamentals are released, sign up for a free FairCurve account.